Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FatP1 RNAi
- Development stage
- Preclinical
- Lead developer
- Charité Universitätsmedizin Berlin
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
FatP1 RNAi refers to an experimental RNA interference construct designed to silence the expression of Fatty Acid Transport Protein 1 (FatP1). In the context of research conducted at Charité - University Medicine Berlin, this tool is used in *Drosophila melanogaster* models to investigate the role of lipid transport in cardiac diastolic function. By utilizing the UAS/GAL4 system for tissue-specific knockdown, researchers demonstrated that reducing FatP1-mediated fatty acid uptake in adipose tissue leads to cardiac lipid overload, mitochondrial dysfunction, and diastolic dysfunction, mimicking aspects of heart failure with preserved ejection fraction (HFpEF). Conversely, cardiac-specific knockdown affects both systolic and diastolic function through different mechanisms.
- Other names
- FatP1 knockdownFatP-1 knockdownFatP 1 knockdownFatp1-RNAiFatp-1-RNAiFatp 1-RNAi
02
Targets
SLC27A1 (Long-chain fatty acid transport protein 1)
Beyond the preview
Go deeper on FatP1 RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FatP1 RNAi.